Tags

Type your tag names separated by a space and hit enter

Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine.
J Neurochem. 1994 Apr; 62(4):1382-9.JN

Abstract

5-Hydroxytryptamine2 (5-HT2) receptor antagonists have been shown to interfere with the stimulation of striatal dopamine synthesis and release produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA). To localize the receptors responsible for the attenuation of MDMA-induced release, 5-HT2 receptor antagonists were infused via the microdialysis probe directly into the brains of awake, freely moving rats before the systemic administration of MDMA. Intrastriatal infusions of the selective 5-HT2 antagonist MDL 100,907 produced a concentration-dependent inhibition of MDMA-induced dopamine release. Similar results were observed with intrastriatal infusions of the 5-HT2 antagonist amperozide. In contrast, infusion of MDL 100,907 into the mid-brain region near the dopaminergic cell bodies was without effect on the MDMA-induced elevation of extracellular dopamine in the ipsilateral striatum. Neither antagonist attenuated basal transmitter efflux nor the MDMA-stimulated release of [3H]dopamine from striatal slices in vitro indicating that the in vivo effect of the antagonists was not due to inhibition of the dopamine uptake carrier. Intrastriatal infusion of tetrodotoxin reduced both basal and MDMA-stimulated dopamine efflux and eliminated the effect of intrastriatal MDL 100,907. The results indicate that 5-HT2 receptors located in the striatum augment the release of dopamine produced by high doses of MDMA. Furthermore, these 5-HT2 receptors appear to be located on nondopaminergic elements of the striatum.

Authors+Show Affiliations

CNS Research, Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7907650

Citation

Schmidt, C J., et al. "Blockade of Striatal 5-hydroxytryptamine2 Receptors Reduces the Increase in Extracellular Concentrations of Dopamine Produced By the Amphetamine Analogue 3,4-methylenedioxymethamphetamine." Journal of Neurochemistry, vol. 62, no. 4, 1994, pp. 1382-9.
Schmidt CJ, Sullivan CK, Fadayel GM. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J Neurochem. 1994;62(4):1382-9.
Schmidt, C. J., Sullivan, C. K., & Fadayel, G. M. (1994). Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. Journal of Neurochemistry, 62(4), 1382-9.
Schmidt CJ, Sullivan CK, Fadayel GM. Blockade of Striatal 5-hydroxytryptamine2 Receptors Reduces the Increase in Extracellular Concentrations of Dopamine Produced By the Amphetamine Analogue 3,4-methylenedioxymethamphetamine. J Neurochem. 1994;62(4):1382-9. PubMed PMID: 7907650.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. AU - Schmidt,C J, AU - Sullivan,C K, AU - Fadayel,G M, PY - 1994/4/1/pubmed PY - 1994/4/1/medline PY - 1994/4/1/entrez SP - 1382 EP - 9 JF - Journal of neurochemistry JO - J Neurochem VL - 62 IS - 4 N2 - 5-Hydroxytryptamine2 (5-HT2) receptor antagonists have been shown to interfere with the stimulation of striatal dopamine synthesis and release produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA). To localize the receptors responsible for the attenuation of MDMA-induced release, 5-HT2 receptor antagonists were infused via the microdialysis probe directly into the brains of awake, freely moving rats before the systemic administration of MDMA. Intrastriatal infusions of the selective 5-HT2 antagonist MDL 100,907 produced a concentration-dependent inhibition of MDMA-induced dopamine release. Similar results were observed with intrastriatal infusions of the 5-HT2 antagonist amperozide. In contrast, infusion of MDL 100,907 into the mid-brain region near the dopaminergic cell bodies was without effect on the MDMA-induced elevation of extracellular dopamine in the ipsilateral striatum. Neither antagonist attenuated basal transmitter efflux nor the MDMA-stimulated release of [3H]dopamine from striatal slices in vitro indicating that the in vivo effect of the antagonists was not due to inhibition of the dopamine uptake carrier. Intrastriatal infusion of tetrodotoxin reduced both basal and MDMA-stimulated dopamine efflux and eliminated the effect of intrastriatal MDL 100,907. The results indicate that 5-HT2 receptors located in the striatum augment the release of dopamine produced by high doses of MDMA. Furthermore, these 5-HT2 receptors appear to be located on nondopaminergic elements of the striatum. SN - 0022-3042 UR - https://www.unboundmedicine.com/medline/citation/7907650/Blockade_of_striatal_5_hydroxytryptamine2_receptors_reduces_the_increase_in_extracellular_concentrations_of_dopamine_produced_by_the_amphetamine_analogue_34_methylenedioxymethamphetamine_ DB - PRIME DP - Unbound Medicine ER -